Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
AssigneesNeovacs, Inserm (Institut National De La Sante Et De La Recherche Medicale), Institut Pasteur
InventorsGéraldine GROUARD-VOGEL, Eva CONDE GARCÌA, Romain BERTRAND, Noémie CAILLOT, Laurent REBER, Pierre BRUHNS, Vincent SERRA
Life of this patent
Estimating the term…
Abstract
An immunogenic product including a cytokine conjugated with a carrier protein, wherein the cytokine is selected from the group including IL-4, IL-13 and mixtures thereof, and wherein the carrier protein is CRM197. Further, a method for manufacturing the immunogenic product. Also, the therapeutic use of the immunogenic product for treating an inflammatory disorder associated with aberrant IL-4 and/or IL-13 expression or activity.
Claims18
An immunogenic product comprising at least one cytokine conjugated with a carrier protein, wherein the at least one cytokine is IL-4, and wherein the carrier protein is CRM197.
Dependencies are inferred from the claim text.